Toshiki Mizuno


Affiliation: Kyoto Prefectural University of Medicine
Country: Japan


  1. Makita N, Yamamoto Y, Nagakane Y, Tomii Y, Mizuno T. Stroke mechanisms and their correlation with functional outcome in medullary infarction. J Neurol Sci. 2019;400:1-6 pubmed publisher
    ..4, p = 0.014). PAD was the most predominant stroke mechanism in MI and generally showed favorable outcome. Patients with LAOD and dissection showed worse outcome than those with PAD. ..
  2. Koizumi T, Mizuta I, Watanabe Hosomi A, Mukai M, Hamano A, Matsuura J, et al. The CADASIL Scale-J, A Modified Scale to Prioritize Access to Genetic Testing for Japanese CADASIL-Suspected Patients. J Stroke Cerebrovasc Dis. 2019;: pubmed publisher
    ..0% and a negative predictive value of 89.2%. In this study, we identified 54 mutations, 7 of which were novel. The CADASIL scale-J is helpful to prioritize access to genetic testing for CADASIL-suspected Japanese patients. ..
  3. Koizumi T, Taguchi K, Mizuta I, Toba H, Ohigashi M, Onishi O, et al. Transiently proliferating perivascular microglia harbor M1 type and precede cerebrovascular changes in a chronic hypertension model. J Neuroinflammation. 2019;16:79 pubmed publisher
    ..Fine-tuning of microglia proliferation and activation could constitute an innovative therapeutic strategy to prevent its development. ..
  4. Yeung W, Mizuta I, Watanabe Hosomi A, Yokote A, Koizumi T, Mukai M, et al. RNF213-related susceptibility of Japanese CADASIL patients to intracranial arterial stenosis. J Hum Genet. 2018;63:687-690 pubmed publisher
    ..1029). We conclude that RNF213 is a gene associated with susceptibility to ICAS in CADASIL patients. MRA follow-up and close observation are necessary for CADASIL patients with the RNF213 variant, as they may be predisposed to ICAS. ..
  5. request reprint
    Mizuno T, Takanashi Y, Onodera H, Shigeta M, Tanaka N, Yuya H, et al. A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement. J Neurol Sci. 2003;213:67-76 pubmed
    ..Cyclophosphamide was effective and there has been no recurrence of symptoms in the last 5 years. We reviewed the non-tumorous LYG/AIL involving the CNS, and discussed the clinical features, MRI imaging and diagnosis of the LYG/AIL...
  6. request reprint
    Mizuno T, Muranishi M, Torugun T, Tango H, Nagakane Y, Kudeken T, et al. Two Japanese CADASIL families exhibiting Notch3 mutation R75P not involving cysteine residue. Intern Med. 2008;47:2067-72 pubmed
    ..These families provide new insights into the diagnosis and pathomechanisms of CADASIL. ..
  7. Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, et al. Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clin Neuropharmacol. 2009;32:113-6 pubmed publisher
    ..Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients...
  8. Mizuta I, Watanabe Hosomi A, Koizumi T, Mukai M, Hamano A, Tomii Y, et al. New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan. J Neurol Sci. 2017;381:62-67 pubmed publisher
    ..Ten mutations were unreported ones. We propose the new criteria of high sensitivity, which will help physicians to assess the need for genetic testing. ..